Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance

Targeting estrogen receptor-positive breast tumors with the XPO1 antagonist selinexor and the tamoxifen byproduct 4-OHT simultaneously rewires the cells’ metabolism to overcome endocrine resistance, University of Illinois researchers found in a new study. The team, from left, graduate student Eylem Kulkoyluoglu-Cotul, food science and human nutrition professor Zeynep Madak-Erdogen, graduate student Brandi Patrice Smith and undergraduate student Kevin Duong. Photo by Fred Zwicky

APR 22, 2019 11:00 AM
SHARITA FORREST

Summary
Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance
Article Name
Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance
Description
Treating breast tumors with two cancer drugs simultaneously may prevent endocrine resistance by attacking the disease along two separate gene pathways, scientists at the University of Illinois found in a new study.